文献速递冠心病血脂与心血管预防

外周血嗜酸性粒细胞计数与冠心病患者血小板高反应性及心原性死亡的双重关联:大规模队列研究

[Dual association of peripheral blood eosinophil count with high on-treatment platelet reactivity and long-term cardiac death in patients with coronary artery disease: a large-scale cohort study].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2026-01-01

结果显示计数降低与血小板高反应性风险增加相关,而计数升高与远期心原性死亡风险增加相关,呈双重关联。

要点

  • 基线嗜酸性粒细胞计数降低与氯吡格雷治疗后血小板高反应性风险增加独立相关。
  • 基线嗜酸性粒细胞计数升高与5年心原性死亡风险增加独立相关。
  • 该双重关联在年龄、性别、糖尿病、高血压等亚组中保持一致。

核心结论

  • 在接受PCI且服用氯吡格雷的冠心病患者中,基线外周血嗜酸性粒细胞计数与血小板高反应性及远期心原性死亡存在双重关联。
  • 计数降低与血小板高反应性风险增加相关,而计数升高与长期心原性死亡风险增加相关。

研究设计与样本

  • 单中心前瞻性队列研究,连续纳入2013年1至12月于中国医学科学院阜外医院行PCI并接受阿司匹林和氯吡格雷双联抗血小板治疗的冠心病患者。
  • 采用血栓弹力图评估血小板反应性,终点事件为心原性死亡。

主要发现

  • 多因素logistic回归显示,作为连续变量,外周血嗜酸性粒细胞计数与血小板高反应性风险呈负相关(OR=0.94,95%CI:0.90~0.98,P=0.003)。
  • 与最低四分位组(Q1组)相比,最高四分位组(Q4组)患者发生血小板高反应性的风险降低(OR=0.77,95%CI:0.65~0.91,P=0.003)。
  • 限制性立方样条分析显示嗜酸性粒细胞计数与血小板高反应性风险之间存在线性负相关(总体P=0.012,非线性P=0.362)。
  • 多因素Cox回归显示,作为连续变量,外周血嗜酸性粒细胞计数与心原性死亡风险呈正相关(HR=1.14,95%CI:1.07~1.21,P<0.001)。
  • 与Q1组相比,Q4组患者发生心原性死亡的风险升高(HR=2.12,95%CI:1.25~3.59,P<0.001)。

关键数值与推荐

  • 亚组分析显示上述关联在年龄、性别、糖尿病、高血压、急性冠脉综合征、体重指数及超敏C反应蛋白各临床亚组中趋势保持一致(交互作用P均>0.05)。
  • 随访期间共发生心原性死亡140例(2.31%)。

临床怎么用

  • 基线嗜酸性粒细胞计数或可辅助识别氯吡格雷治疗后血小板高反应性风险较高的冠心病患者。
  • 基线嗜酸性粒细胞计数升高或可提示PCI术后患者远期心原性死亡风险增加,需加强随访管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the association of baseline peripheral blood eosinophil count with high on-treatment platelet reactivity and its clinical prognostic value in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) and receiving clopidogrel. Methods: This was a single-center prospective cohort study. Consecutive patients with coronary artery disease who underwent PCI at Fuwai Hospital, Chinese Academy of Medical Sciences, between January and December 2013 were enrolled; those receiving dual antiplatelet therapy with aspirin and clopidogrel were included. Baseline data were collected, and platelet reactivity was assessed using thromboelastography. Patients were followed up for 5 years, with cardiac death as the endpoint. Baseline eosinophil count was analyzed as a continuous variable and was also categorized into quartiles (Q1-Q4). Multivariable logistic regression was used to analyze the association between eosinophil count and high on-treatment platelet reactivity. Multivariable restricted cubic spline models were used to analyze the dose-response relationship. Subgroup analyses and interaction tests were performed according to age, sex, diabetes, hypertension, acute coronary syndrome, body mass index, and high-sensitivity C-reactive protein levels. Multivariable Cox proportional hazards regression was used to assess the predictive value of eosinophil count for cardiac death. Results: A total of 6 524 patients were included. The mean age was (58.21±10.26) years, and 5 059 (77.54%) were male. Among them, 6 050 patients completed the 5-year follow-up, and 140 cardiac deaths (2.31%) occurred. Multivariable logistic regression analysis showed that peripheral blood eosinophil count was negatively associated with the risk of high on-treatment platelet reactivity (OR=0.94, 95%CI: 0.90-0.98, P=0.003). When analyzed as a categorical variable, compared with the lowest quartile group (Q1), the risk of high on-treatment platelet reactivity was lower in patients in the highest quartile group (Q4) (OR=0.77, 95%CI: 0.65-0.91, P=0.003). Multivariable restricted cubic spline analysis showed a linear negative correlation between eosinophil count and the risk of high on-treatment platelet reactivity (P for overall=0.012, P for nonlinearity=0.362). Further subgroup analysis showed that the above association remained consistent across clinical subgroups stratified by age, sex, diabetes, hypertension, acute coronary syndrome, body mass index, and high-sensitivity C-reactive protein levels (all P for interaction>0.05). Multivariable Cox regression analysis showed that peripheral blood eosinophil count was positively associated with the risk of cardiac death (HR=1.14, 95%CI: 1.07-1.21, P<0.001). When analyzed as a categorical variable, compared with the Q1 group, the risk of cardiac death was higher in patients in the Q4 group (HR=2.12, 95%CI: 1.25-3.59, P<0.001). Conclusions: In patients with coronary artery disease undergoing PCI and receiving clopidogrel, baseline peripheral blood eosinophil count showed a dual association with high on-treatment platelet reactivity and long-term cardiac death. A lower count was associated with an increased risk of high on-treatment platelet reactivity, whereas an elevated count was associated with an increased long-term risk of cardiac death. 目的: 探讨接受经皮冠状动脉介入治疗(PCI)且服用氯吡格雷的冠心病患者,基线外周血嗜酸性粒细胞计数与血小板高反应性风险的相关性及其临床预后价值。 方法: 本研究基于一项单中心前瞻性队列研究,连续纳入2013年1至12月于中国医学科学院阜外医院行PCI治疗的冠心病患者,选取其中接受阿司匹林和氯吡格雷双联抗血小板治疗的患者。收集患者的基线资料,采用血栓弹力图评估其血小板反应性。对患者进行5年随访,终点事件为心原性死亡。将基线嗜酸性粒细胞计数作为连续变量进行分析,同时根据四分位数分为Q1~Q4组。采用多因素logistic回归模型分析嗜酸性粒细胞计数与血小板高反应性的关联,采用多因素限制性立方样条模型分析剂量-反应关系,并按年龄、性别、糖尿病、高血压、急性冠脉综合征、体重指数及超敏C反应蛋白水平进行多因素logistic回归亚组分析和交互作用检验。采用多因素Cox比例风险回归模型评估其对心原性死亡的预测价值。 结果: 共纳入6 524例患者,年龄(58.21±10.26)岁,男性5 059例(77.54%),其中6 050例患者完成5年随访,发生心原性死亡140例(2.31%)。多因素logistic回归分析结果显示,作为连续变量时,外周血嗜酸性粒细胞计数与血小板高反应性风险呈负相关(OR=0.94,95%CI:0.90~0.98,P=0.003);作为四分位数分类变量时,与最低四分位组(Q1组)相比,最高四分位组(Q4组)患者发生血小板高反应性的风险降低(OR=0.77,95%CI:0.65~0.91,P=0.003)。多因素限制性立方样条分析显示嗜酸性粒细胞计数与血小板高反应性风险之间存在线性负相关关系(总体P=0.012,非线性P=0.362)。进一步亚组分析显示,上述关联在年龄、性别、糖尿病、高血压、急性冠脉综合征、体重指数及超敏C反应蛋白各临床亚组中趋势保持一致(交互作用P均>0.05)。多因素Cox回归分析结果显示,作为连续变量时,外周血嗜酸性粒细胞计数与心原性死亡风险呈正相关(HR=1.14,95%CI:1.07~1.21,P<0.001);作为四分位数分类变量时,与Q1组相比,Q4组患者发生心原性死亡的风险升高(HR=2.12,95%CI:1.25~3.59,P<0.001)。 结论: 在接受PCI且服用氯吡格雷的冠心病患者中,基线外周血嗜酸性粒细胞计数与血小板高反应性及远期心原性死亡存在双重关联,计数降低与血小板高反应性风险增加相关,而计数升高则与长期心原性死亡风险增加相关。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Ke ZH, Yan KL, Yuan DS, et al. [Dual association of peripheral blood eosinophil count with high on-treatment platelet reactivity and long-term cardiac death in patients with coronary artery disease: a large-scale cohort study]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 42907222. doi:10.3760/cma.j.cn112148-20260313-00166

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。